checkAd

     548  0 Kommentare Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram

    DUBLIN, Nov. 8, 2017 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the appointment of Sharad S. Mansukani, M.D., CPE, CMCE to the Company's Board of Directors effective immediately.  Endo also announced Douglas S. Ingram's decision to resign as a director from the Company's Board of Directors effective November 6, 2017 due to his appointment as President and CEO of Sarepta Therapeutics earlier this year.

    "I'm pleased to welcome Dr. Mansukani to the Endo Board. We value the unique skill set he brings and look forward to his contributions as we continue to execute against the key priorities that we believe will enable us to achieve our Company's vision," said Roger Kimmel, Chairman of the Board of Endo.

    "Dr. Mansukani will be an excellent addition to our Board of Directors. He possesses significant board experience and deep healthcare experience which should prove to be of great value to Endo," said Paul Campanelli, President and Chief Executive Officer of Endo.

    Dr. Mansukani stated, "I look forward to working closely with Endo's Board of Directors and leadership team. It is a challenging time for the industry and I'm eager to be a resource as they continue to reshape the organization for success. I am enthusiastic about the future of the Company and the opportunities ahead."

    Dr. Mansukani currently serves as a Senior Advisor to TPG Capital LP and on the Board of Directors of Kindred Healthcare, Inc. He previously served on the Board of Directors of IASIS Healthcare, Surgical Care Affiliates, IMS Health Holdings, Inc. and as Vice Chairman of the Board of Directors of HealthSpring, Inc. as well as a Strategic Advisor to the Board of Directors of Cigna Corporation. Additionally, Dr. Mansukani was a member of Medicare's Program Advisory and Oversight Committee and served as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services.  Dr. Mansukani completed a residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine and a fellowship in quality management and managed care at the Wharton School of Business. 

    Seite 1 von 2



    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram DUBLIN, Nov. 8, 2017 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) today announced the appointment of Sharad S. Mansukani, M.D., CPE, CMCE to the Company's Board of Directors effective immediately.  Endo also announced Douglas S. Ingram's …

    Schreibe Deinen Kommentar

    Disclaimer